JP2018531982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531982A5 JP2018531982A5 JP2018522556A JP2018522556A JP2018531982A5 JP 2018531982 A5 JP2018531982 A5 JP 2018531982A5 JP 2018522556 A JP2018522556 A JP 2018522556A JP 2018522556 A JP2018522556 A JP 2018522556A JP 2018531982 A5 JP2018531982 A5 JP 2018531982A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- hydrogen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 154
- 150000001875 compounds Chemical class 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 42
- 125000002947 alkylene group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 208000023504 respiratory system disease Diseases 0.000 claims description 24
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000003566 oxetanyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 10
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 10
- 206010006448 Bronchiolitis Diseases 0.000 claims description 9
- 230000000414 obstructive effect Effects 0.000 claims description 9
- YEGFDJOAFMPJSE-UHFFFAOYSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CCN(CC2)C)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CCN(CC2)C)N=1 YEGFDJOAFMPJSE-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 206010035742 Pneumonitis Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 206010069351 acute lung injury Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 3
- HROWLWGDTOBEDM-UHFFFAOYSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CN(C2)C)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CN(C2)C)N=1 HROWLWGDTOBEDM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- PRNDBSRPZSZAPK-UHFFFAOYSA-N C(C)(CC)N(CCN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)C Chemical compound C(C)(CC)N(CCN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)C PRNDBSRPZSZAPK-UHFFFAOYSA-N 0.000 claims description 2
- VKFCLOVOQMXKJM-UHFFFAOYSA-N C(C)(CC)N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F Chemical compound C(C)(CC)N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F VKFCLOVOQMXKJM-UHFFFAOYSA-N 0.000 claims description 2
- YKKSLFAFHDNXRX-UHFFFAOYSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CN(C2)C(C)C)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C2CN(C2)C(C)C)N=1 YKKSLFAFHDNXRX-UHFFFAOYSA-N 0.000 claims description 2
- AOGXHIHTHRCTPK-UHFFFAOYSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCN(C)CC)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCN(C)CC)N=1 AOGXHIHTHRCTPK-UHFFFAOYSA-N 0.000 claims description 2
- ZFFSYYHNBNAIRW-KRWDZBQOSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCN2[C@H](CCC2)C)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCN2[C@H](CCC2)C)N=1 ZFFSYYHNBNAIRW-KRWDZBQOSA-N 0.000 claims description 2
- SNPLAOHHBAWLMU-UHFFFAOYSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCNC2CC(C2)OC)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)CCNC2CC(C2)OC)N=1 SNPLAOHHBAWLMU-UHFFFAOYSA-N 0.000 claims description 2
- JBYYBYKZQWGOJL-KRWDZBQOSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C[C@@H]2NCCOC2)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C[C@@H]2NCCOC2)N=1 JBYYBYKZQWGOJL-KRWDZBQOSA-N 0.000 claims description 2
- JBYYBYKZQWGOJL-QGZVFWFLSA-N C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C[C@H]2NCCOC2)N=1 Chemical compound C(C)C=1C(=CC(=C(C=1)O)F)C1=CC=C2C(=NNC2=C1)C=1NC2=C(CN(CC2)C[C@H]2NCCOC2)N=1 JBYYBYKZQWGOJL-QGZVFWFLSA-N 0.000 claims description 2
- CUIBPLIFKMBESI-UHFFFAOYSA-N C1(CC1)N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F Chemical compound C1(CC1)N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F CUIBPLIFKMBESI-UHFFFAOYSA-N 0.000 claims description 2
- FLPXNQWEAODYRF-UHFFFAOYSA-N CN(CC(CN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)F)C Chemical compound CN(CC(CN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)F)C FLPXNQWEAODYRF-UHFFFAOYSA-N 0.000 claims description 2
- YXKUPJSJNAKRLQ-UHFFFAOYSA-N CN(CCN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)C Chemical compound CN(CCN1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F)C YXKUPJSJNAKRLQ-UHFFFAOYSA-N 0.000 claims description 2
- HGQQGQFLBDQYCO-UHFFFAOYSA-N N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F Chemical compound N1CC(C1)N1CC2=C(CC1)NC(=N2)C1=NNC2=CC(=CC=C12)C1=CC(=C(C=C1CC)O)F HGQQGQFLBDQYCO-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 0 CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CN(*)CC3)c3[n]1)n[n]2 Chemical compound CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CN(*)CC3)c3[n]1)n[n]2 0.000 description 14
- UPJNSCOYLNAEKD-UHFFFAOYSA-N Brc(cc1)cc2c1c(-c1nc(CN(Cc3ccccc3)CC3)c3[nH]1)n[nH]2 Chemical compound Brc(cc1)cc2c1c(-c1nc(CN(Cc3ccccc3)CC3)c3[nH]1)n[nH]2 UPJNSCOYLNAEKD-UHFFFAOYSA-N 0.000 description 2
- ZTQVHAJNEIOLPB-UHFFFAOYSA-N CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CNCC3)c3[nH]1)n[nH]2 Chemical compound CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CNCC3)c3[nH]1)n[nH]2 ZTQVHAJNEIOLPB-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- -1 tetrahydropyran-4-yl Chemical group 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- DLABLFPCTXRQMY-UHFFFAOYSA-N CC1CSCC1 Chemical compound CC1CSCC1 DLABLFPCTXRQMY-UHFFFAOYSA-N 0.000 description 1
- XBSDJXNXYCRWDX-UHFFFAOYSA-N CNC(C1)CC1OC Chemical compound CNC(C1)CC1OC XBSDJXNXYCRWDX-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250113P | 2015-11-03 | 2015-11-03 | |
| US62/250,113 | 2015-11-03 | ||
| PCT/US2016/059999 WO2017079205A1 (en) | 2015-11-03 | 2016-11-02 | Jak kinase inhibitor compounds for treatment of respiratory disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531982A JP2018531982A (ja) | 2018-11-01 |
| JP2018531982A5 true JP2018531982A5 (enExample) | 2019-09-26 |
| JP6800969B2 JP6800969B2 (ja) | 2020-12-16 |
Family
ID=57442794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522556A Expired - Fee Related JP6800969B2 (ja) | 2015-11-03 | 2016-11-02 | 呼吸器疾患の処置のためのｊａｋキナーゼ阻害剤化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10100049B2 (enExample) |
| EP (1) | EP3371186A1 (enExample) |
| JP (1) | JP6800969B2 (enExample) |
| KR (1) | KR20180073687A (enExample) |
| CN (1) | CN108349972B (enExample) |
| AU (1) | AU2016350816B2 (enExample) |
| BR (1) | BR112018008966B1 (enExample) |
| CA (1) | CA3001542C (enExample) |
| CL (1) | CL2018001145A1 (enExample) |
| CO (1) | CO2018005640A2 (enExample) |
| EA (1) | EA034914B1 (enExample) |
| HK (1) | HK1252685A1 (enExample) |
| IL (1) | IL258772B (enExample) |
| MX (1) | MX374605B (enExample) |
| MY (1) | MY195427A (enExample) |
| NZ (1) | NZ741737A (enExample) |
| PH (1) | PH12018500828B1 (enExample) |
| SA (1) | SA518391470B1 (enExample) |
| TW (1) | TWI710560B (enExample) |
| UA (1) | UA123633C2 (enExample) |
| WO (1) | WO2017079205A1 (enExample) |
| ZA (1) | ZA201802496B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| EP3831830A1 (en) | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| TWI754019B (zh) * | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| AU2018261588A1 (en) * | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| EP3619208B1 (en) * | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
| US20200281857A1 (en) | 2017-11-22 | 2020-09-10 | Dauntless 1, Inc. | Therapeutic compound formulations |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| BR112021004087A2 (pt) * | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| DK3837258T3 (da) * | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| WO2020106751A1 (en) * | 2018-11-19 | 2020-05-28 | New York University | Inhinitors of gli1 as therapeutic agents |
| KR102873783B1 (ko) | 2019-02-25 | 2025-10-21 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
| US12698289B2 (en) | 2019-02-25 | 2026-08-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Solid forms of pharmaceutically acceptable salts of (S)-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(3-hydroxypyrrolidin-1-yl)methanone as JAK inhibitors |
| CN114075200A (zh) * | 2020-08-14 | 2022-02-22 | 河南迈英诺医药科技有限公司 | 用于治疗重症肺炎的jak抑制剂化合物 |
| UA130579C2 (uk) | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| JP7580136B2 (ja) * | 2019-12-30 | 2024-11-11 | 路良 | Ｊａｋ阻害剤化合物及びその使用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20220149585A (ko) | 2020-03-02 | 2022-11-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 화합물의 결정성 수화물 |
| TW202207934A (zh) * | 2020-03-27 | 2022-03-01 | 瑞典商阿斯特捷利康公司 | 用於肺遞送的乾粉配製物及使用方法 |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CA3212635A1 (en) | 2021-03-26 | 2022-09-29 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a dihydrochloride salt of a jak inhibitor compound |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| CN119403552A (zh) | 2022-05-05 | 2025-02-07 | 施万生物制药研发Ip有限责任公司 | 用于通过雾化口腔吸入递送的奈珠西替尼 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| WO2010039825A2 (en) | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| MX337849B (es) | 2009-07-28 | 2016-03-09 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| SMT201700581T1 (it) * | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
| LT3077395T (lt) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| EP3831830A1 (en) | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| EP3619208B1 (en) | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| CA3212635A1 (en) | 2021-03-26 | 2022-09-29 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a dihydrochloride salt of a jak inhibitor compound |
-
2016
- 2016-11-02 TW TW105135436A patent/TWI710560B/zh not_active IP Right Cessation
- 2016-11-02 PH PH1/2018/500828A patent/PH12018500828B1/en unknown
- 2016-11-02 WO PCT/US2016/059999 patent/WO2017079205A1/en not_active Ceased
- 2016-11-02 NZ NZ741737A patent/NZ741737A/en unknown
- 2016-11-02 EA EA201891091A patent/EA034914B1/ru unknown
- 2016-11-02 KR KR1020187015680A patent/KR20180073687A/ko not_active Withdrawn
- 2016-11-02 MX MX2018005446A patent/MX374605B/es active IP Right Grant
- 2016-11-02 MY MYPI2018701385A patent/MY195427A/en unknown
- 2016-11-02 JP JP2018522556A patent/JP6800969B2/ja not_active Expired - Fee Related
- 2016-11-02 CA CA3001542A patent/CA3001542C/en active Active
- 2016-11-02 CN CN201680063886.1A patent/CN108349972B/zh not_active Expired - Fee Related
- 2016-11-02 BR BR112018008966-4A patent/BR112018008966B1/pt not_active IP Right Cessation
- 2016-11-02 UA UAA201806062A patent/UA123633C2/uk unknown
- 2016-11-02 AU AU2016350816A patent/AU2016350816B2/en not_active Ceased
- 2016-11-02 HK HK18111992.5A patent/HK1252685A1/zh unknown
- 2016-11-02 EP EP16804947.6A patent/EP3371186A1/en not_active Withdrawn
- 2016-11-02 US US15/341,226 patent/US10100049B2/en active Active
-
2018
- 2018-04-16 ZA ZA2018/02496A patent/ZA201802496B/en unknown
- 2018-04-17 IL IL258772A patent/IL258772B/en active IP Right Grant
- 2018-04-30 SA SA518391470A patent/SA518391470B1/ar unknown
- 2018-04-30 CL CL2018001145A patent/CL2018001145A1/es unknown
- 2018-05-29 CO CONC2018/0005640A patent/CO2018005640A2/es unknown
- 2018-07-18 US US16/038,424 patent/US10183942B2/en active Active
- 2018-12-10 US US16/215,194 patent/US10526330B2/en active Active
-
2019
- 2019-11-20 US US16/689,706 patent/US10913740B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 US US17/248,015 patent/US11299492B2/en not_active Expired - Fee Related
-
2022
- 2022-03-07 US US17/688,001 patent/US11718616B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6918819B2 (ja) | オルトミクソウイルス感染の処置に有用な三環式化合物 | |
| US11084784B2 (en) | ROR-gamma modulators and uses thereof | |
| JP2025031810A (ja) | 化合物、組成物、及び、方法 | |
| ES2593331T3 (es) | Dihidropirazolonas sustituidas y su uso como inhibidores de la HIF-prolil-4-hidroxilasa | |
| JP2020529987A5 (enExample) | ||
| JP2010513283A5 (enExample) | ||
| HU228960B1 (hu) | Ftalazinon-származékok | |
| JP2004522792A5 (enExample) | ||
| CN102099355A (zh) | 苯基和苯并二氧杂环己烯基取代的吲唑衍生物 | |
| JP2009073859A (ja) | 置換シクロペンタン誘導体の調製方法及びその新規結晶構造 | |
| WO2021203023A1 (en) | Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) | |
| JP2022540922A5 (enExample) | ||
| JP2015516968A5 (enExample) | ||
| JP2022523368A5 (enExample) | ||
| JP2004269469A (ja) | ピリミジン誘導体又はその塩 | |
| ES2563440T3 (es) | Compuestos de piperidina inhibidores de prostaglandina D sintasa | |
| JP2015524483A5 (enExample) | ||
| AU2017303898A1 (en) | Production method for pyrazole-amide compound | |
| JP2008516935A (ja) | フェノキシベンズアミド化合物の製造方法 | |
| JP2020517676A5 (enExample) | ||
| CN118076348A (zh) | 能够抑制nav 1.7和/或nav 1.8的n-酰基腙化合物、其制备方法、组合物、用途、使用其的治疗方法和试剂盒 | |
| JPWO1997034873A1 (ja) | アミノピリジン誘導体 | |
| JP2021534084A5 (enExample) | ||
| CN111936488A (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| US20200165225A1 (en) | Bace1 inhibitors for treatment of alzheimer's disease |